You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中国再生医学(08158.HK)拟折让5.7%配售5亿股 并发1.2亿元可换股债券
阿思达克 03-03 09:24
中国再生医学(08158.HK)公布,计划向不少於六名承配人配售最多5亿股,占公司现有已发行股本约56.84%及发行配售股份扩大已发行股本约36.25%。每股配售价0.2元,较3月2日收市价0.212元折让约5.66%。同时,公司於3月2日与与认购人全辉控股订立认购及清偿协议,拟发行1.2亿元的可换股债券,并於完成时透过抵销股东贷款支付认购价,换股价初步为0.2元。悉数行使可换股债券随附换股权後,将配发最多6亿股换股股份,相当於公司已发行股份约68.24%,及於悉数行使可换股债券随附换股权後,经配发及发行换股股份扩大後已发行股份约40.56%。(gc/k)~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account